Aurora kinase inhibitor-2是一种 Aurora 激酶抑制剂，通过干扰 Aurora 激酶的活性，阻断细胞周期进程，具有抗癌潜力，特别是在乳腺癌和卵巢癌研究中。

AKI603是一种针对 AurA 的抑制剂，展示了克服白血病中的耐药性突变和抗增殖活性的潜力。

Chiauranib是一种口服有效的多靶点抑制剂，主要靶向血管生成相关激酶如VEGFR和PDGFR。它对癌症具有强大的抗肿瘤活性，并在血管生成抑制研究中具有潜力。

Barasertib (AZD1152) 是 Barasertib-hQPA 的前药，是一种高选择性的 Aurora B 抑制剂，IC50 为 0.37 nM。Barasertib (AZD1152) 可诱导癌细胞生长停滞和凋亡。

GSK1070916 is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM and displays > 100-fold selectivity against the closely related Aurora A-TPX2 complex (IC50=490 nM).

Barasertib-HQPA (AZD2811) 是一种高度选择性的极光激酶 B 抑制剂，在非细胞试验中的 IC50 值为 0.37 nM，可引起癌细胞生长阻滞和凋亡。

MK-5108 is a potent and highly selective Aurora inhibitor with IC50 of 0.064, 14 and 12 nM for Aurora A, B and C.

CCT 137690 是一种有效的口服活性极光激酶抑制剂，对极光激酶 A、B 和 C 的 IC50 值分别为 15、25 和 19 nM。

MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM and exhibits more than 40-fold selective for Aurora A than Aurora B.

CCT129202 is a Aurora kinase inhibitor with IC50 of 0.042 ± 0.022, 0.198 ± 0.05, and 0.227 ± 0.064 μM for Aurora A, Aurora B, and Aurora C, respectively.

PHA-680632 is potent inhibitor of Aurora A, B and C with IC50 of 27 nM, 135 nM and 120 nM, respectively.

SNS-314 is a potent and selective inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 9 nM, 31 nM, and 3 nM, respectively.

TAK-901 is an inhibitor of Aurora A/B with IC50 of 21 nM/15 nM.

Tozasertib is the inhibitor of Aurora-A, -B, -C kinases with Ki values of 0.6, 18, 4.6 nM respectively.

AMG-900 is a potent and highly selective pan-Aurora kinases inhibitor for Aurora A/B/C with IC50 of 5 nM/4 nM /1 nM, and is > 10-fold selective for Aurora kinases than p38α, Tyk2, JNK2, Met and Tie2.

Aurora an inhibitor I is a potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold selective for Aurora A than Aurora B.

SP-96 is a highly selective and non-ATP-competitive Aurora A/B inhibitor with IC50 values of 0.316nM 18.975 nM for Aurora A and Aurora B, respectively.

Hesperadin is a potent and ATP-competitive inhibitor of Aurora B kinase with IC50 of 250 nM.

Alisertib (MLN 8237) 是一种口服活性和选择性的 Aurora A 激酶抑制剂 (IC50 = 1.2 nM)，通过结合 Aurora A 激酶引起纺锤体异常和有丝分裂积累。Alisertib (MLN 8237) 通过靶向 AKT/mTOR/AMPK/p38 通路在白血病细胞中诱导凋亡和自噬，显示出抗肿瘤活性。

JNJ-7706621 is a pan-CDK inhibitor that inhibits CDK1/2 with IC50 of 9/4 nM, also potently inhibits Aurora A/B.